Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 17/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27359449 | 0.82 | MGLL (0.39) | MGLL | |
| SCHEMBL24268265 | 0.82 | CDK8 (0.35) | MGLLCDK8CDK19 | |
| SCHEMBL25051770 | 0.81 | MGLL (0.37) | MGLL | |
| SCHEMBL9966019 | 0.80 | NEK2 (0.42) | MGLLCDK8CDK19 | |
| SCHEMBL25037639 | 0.77 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL12544783 | 0.77 | — | — | |
| SCHEMBL23219683 | 0.76 | CDK8 (0.37) | MGLLCDK8CDK19 | |
| SCHEMBL22053045 | 0.76 | KDM4E (0.37) | MGLLCDK8CDK19 | |
| SCHEMBL22783779 | 0.76 | MGLL (0.38) | MGLLCDK8CDK19 | |
| SCHEMBL18925948 | 0.74 | CYP2D6 (0.39) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9221809-B2 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | MGLL 4659/4885CDK8 871/4885CDK19 689/4885 |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | MGLL 3698/4885CDK8 362/4885CDK19 213/4885 |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | PIK3R5, PIK3CA, PIK3CD | MGLL 4061/4885CDK8 355/4885CDK19 226/4885 |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | MGLL 3698/4885CDK8 362/4885CDK19 213/4885 |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | MGLL 4755/4885CDK8 554/4885CDK19 791/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | MGLL 4354/4885CDK8 1173/4885CDK19 1055/4885 |
| US-20230125684-A1 | Aryl Sulfonyl Compounds as CCR6 Inhibitors | CCR6, CCR1, CCR3 | MGLL 3590/4885CDK8 924/4885CDK19 1433/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | MGLL 4179/4885CDK8 4257/4885CDK19 4116/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | MGLL 4061/4885CDK8 355/4885CDK19 226/4885 |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | MGLL 4061/4885CDK8 355/4885CDK19 226/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | MGLL 4061/4885CDK8 355/4885CDK19 226/4885 |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | MGLL 4061/4885CDK8 355/4885CDK19 226/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | MGLL 4496/4885CDK8 767/4885CDK19 1562/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | MGLL 4061/4885CDK8 355/4885CDK19 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.